Analysed INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) News Sources
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
16-07-2026
yahoo.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
10-08-2026
yahoo.com
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...
14-05-2026
yahoo.com
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission
15-05-2026
yahoo.com
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
11-06-2026
yahoo.com
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment
19-06-2026
yahoo.com
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
11-08-2026
yahoo.com
What is the current price of INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ)?
The current price of INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) is $3.99.
INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) since the previous trading day is $-0.03.
INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) since the previous trading day is -0.7463%.
What is the most recent average sentiment score for INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ)?
The most recent average sentiment score for INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ)?
The most recent sentiment for INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ) is .
SEC-8K** Filing Available For INSIGHT MOLECULAR DIAGNOSTIC (IMDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.